LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 155

Search options

  1. Article ; Online: Risk of COVID-19 in Patients With Cancer.

    Maitland, Michael L / Heyer, David / Gomberg-Maitland, Mardi

    JAMA oncology

    2020  Volume 6, Issue 9, Page(s) 1471

    MeSH term(s) Betacoronavirus ; COVID-19 ; China ; Coronavirus Infections ; Humans ; Neoplasms/epidemiology ; Pandemics ; Pneumonia, Viral ; SARS Virus ; SARS-CoV-2 ; Tertiary Care Centers
    Keywords covid19
    Language English
    Publishing date 2020-06-18
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2020.2583
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Improving clinical trial design through quantitative pharmacology.

    Maitland, Michael L

    Clinical advances in hematology & oncology : H&O

    2016  Volume 14, Issue 8, Page(s) 606–608

    MeSH term(s) Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Computer Simulation ; Drug Discovery ; Humans ; Models, Theoretical ; Neoplasms/drug therapy ; Pharmacology/methods ; Research Design ; Treatment Outcome
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2016-08
    Publishing country United States
    Document type Interview
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply.

    Gillmore, Julian D / Maitland, Michael L / Lebwohl, David

    The New England journal of medicine

    2021  Volume 385, Issue 18, Page(s) 1722–1723

    MeSH term(s) Amyloid Neuropathies, Familial/genetics ; Amyloid Neuropathies, Familial/therapy ; CRISPR-Cas Systems ; Gene Editing ; Humans ; RNA, Guide, CRISPR-Cas Systems
    Chemical Substances RNA, Guide, CRISPR-Cas Systems
    Language English
    Publishing date 2021-08-24
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2114592
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Model-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.

    Salem, Ahmed M / Dvergsten, Erik / Karovic, Sanja / Maitland, Michael L / Gopalakrishnan, Mathangi

    CPT: pharmacometrics & systems pharmacology

    2023  Volume 12, Issue 7, Page(s) 929–940

    Abstract: Taxanes are currently the most frequently used chemotherapeutic agents in cancer care, where real-world use has focused on minimizing adverse events and standardizing the delivery. Myelosuppression is a well-characterized, adverse pharmacodynamic effect ... ...

    Abstract Taxanes are currently the most frequently used chemotherapeutic agents in cancer care, where real-world use has focused on minimizing adverse events and standardizing the delivery. Myelosuppression is a well-characterized, adverse pharmacodynamic effect of taxanes. Electronic health records (EHRs) comprise data collected during routine clinical care that include patients with heterogeneous demographic, clinical, and treatment characteristics. Application of pharmacokinetic/pharmacodynamic (PK/PD) modeling to EHR data promises new insights on the real-world use of taxanes and strategies to improve therapeutic outcomes especially for populations who are typically excluded from clinical trials, including the elderly. This investigation: (i) leveraged previously published PK/PD models developed with clinical trial data and addressed challenges to fit EHR data, and (ii) evaluated predictors of paclitaxel-induced myelosuppression. Relevant EHR data were collected from patients treated with paclitaxel-containing chemotherapy at Inova Schar Cancer Institute between 2015 and 2019 (n = 405). Published PK models were used to simulate mean individual exposures of paclitaxel and carboplatin, which were linearly linked to absolute neutrophil count (ANC) using a published semiphysiologic myelosuppression model. Elderly patients (≥70 years) constituted 21.2% of the dataset and 2274 ANC measurements were included in the analysis. The PD parameters were estimated and matched previously reported values. The baseline ANC and chemotherapy regimen were significant predictors of paclitaxel-induced myelosuppression. The nadir ANC and use of supportive treatments, such as growth factors and antimicrobials, were consistent across age quantiles suggesting age had no effect on paclitaxel-induced myelosuppression. In conclusion, EHR data could complement clinical trial data in answering key therapeutic questions.
    MeSH term(s) Humans ; Aged ; Paclitaxel ; Taxoids/adverse effects ; Carboplatin ; Neutrophils ; Neoplasms/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
    Chemical Substances Paclitaxel (P88XT4IS4D) ; Taxoids ; Carboplatin (BG3F62OND5)
    Language English
    Publishing date 2023-04-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2697010-7
    ISSN 2163-8306 ; 2163-8306
    ISSN (online) 2163-8306
    ISSN 2163-8306
    DOI 10.1002/psp4.12963
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Risk of COVID-19 in Patients With Cancer

    Maitland, Michael L. / Heyer, David / Gomberg-Maitland, Mardi

    JAMA Oncology

    2020  Volume 6, Issue 9, Page(s) 1471

    Keywords General Medicine ; covid19
    Language English
    Publisher American Medical Association (AMA)
    Publishing country us
    Document type Article ; Online
    ISSN 2374-2437
    DOI 10.1001/jamaoncol.2020.2583
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Book ; Online: Risk of COVID-19 in Patients With Cancer.

    Maitland, Michael L / Heyer, David / Gomberg-Maitland, Mardi

    Medicine Faculty Publications

    2020  

    Keywords Medicine and Health Sciences ; covid19
    Publishing date 2020-07-02T07:00:00Z
    Publisher Health Sciences Research Commons
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Book ; Online: Risk of COVID-19 in Patients With Cancer.

    Maitland, Michael L / Heyer, David / Gomberg-Maitland, Mardi

    COVID-19 Publications by GWU Authors

    2020  

    Keywords covid19
    Publishing date 2020-07-02T07:00:00Z
    Publisher Health Sciences Research Commons
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: More sound cancer therapy biomarker development with active noise control.

    Maitland, Michael L

    The oncologist

    2013  Volume 18, Issue 3, Page(s) 239–241

    MeSH term(s) Antibodies, Monoclonal, Humanized/adverse effects ; Bevacizumab ; Humans ; Hypertension/chemically induced
    Chemical Substances Antibodies, Monoclonal, Humanized ; Bevacizumab (2S9ZZM9Q9V)
    Language English
    Publishing date 2013-03-13
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1634/theoncologist.2013-0030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Cancer Clinical Investigators Should Converge with Pharmacometricians.

    Maitland, Michael L / O'Cearbhaill, Roisin E / Gobburu, Jogarao

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2019  Volume 25, Issue 17, Page(s) 5182–5184

    Abstract: The applied quantitative science pharmacometrics has significantly enhanced cancer therapeutics development. Pharmacometrics is now improving our understanding of complex diagnostics. Through the concept of convergence and methods of quantitative and ... ...

    Abstract The applied quantitative science pharmacometrics has significantly enhanced cancer therapeutics development. Pharmacometrics is now improving our understanding of complex diagnostics. Through the concept of convergence and methods of quantitative and systems pharmacology, pharmacometrics is poised to interconnect mathematical models of disease and therapy to advance cancer care.
    MeSH term(s) Carcinoma, Ovarian Epithelial ; Female ; Humans ; Kinetics ; Ovarian Neoplasms ; Research Personnel
    Language English
    Publishing date 2019-06-27
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-19-1067
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top